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Papulo- and vesiculo-necrotic lesions are rare manifestations of secondary syphilis. Until now it has been described
only in HIV-infected patients with advanced stages of immunosuppression. This case report describes an unusual
case of PLEVA-like syphilis in a 33-year-old man with newly diagnosed HIV infection. Despite that the CD4 cells lev-
el and viral load did not indicate the advance stage of immunosuppression, the unusual manifestation of syphilis
and neurosyphilis occurred. The presented case indicates the need for HIV screening in every patient with syphilis
especially when the clinical manifestation is unusual. Importance of syphilis testing in every case with atypical rash-
es should be also highlighted.
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Introduction
Syphilis is a sexually transmitted infection caused by
Treponema pallidum. The secondary stage is character-
ized by the high variability of cutaneous findings. How-
ever, unusual clinical manifestations of syphilis may be
more common in HIV-infected patients [1]. 
Case report
A 33-year-old otherwise healthy homosexual man pre-
sented at the dermatology clinic with a 3-week history of
progressive, non-pruritic rash associated with mild
headache and photophobia. Two weeks prior, chicken pox
was diagnosed in the patient and treatment with acyclovir
was started. 
The skin examination revealed numerous, randomly
scattered papules of various size and plaques on the face,
trunk, and extremities (Figure 1). Some of the lesions
showed central necrosis (Figure 2). Generalized lym-
phadenopathy was present. Neurological examination
revealed no abnormalities. 
Blood serology for syphilis was positive (VDRL 1/128,
TPHA: positive, FTA 1/32000, FTA-ABS: positive). Both ELISA
and Western blot tests for HIV were positive. The CD4 cells
level was 430/µl and HIV RNA load was 25 000 copies/ml.
Negative results were obtained for tests for hepatitis B
and C. Cerebrospinal fluid (CSF) examination showed the
elevated white blood count (30 cells/µl, 100% of lym-
phocytes), elevated protein concentration (85 mg/dl;
range to 45 mg/dl), positive CSF-VDRL and CSF-TPHA.
Syphilis, neurosyphilis and HIV infection were diagnosed.
The patient was treated with crystalline penicillin intra-
venously at a dose of 24 million units per day, for 21 days.
Skin lesions cleared completely and blood VDRL titer
declined to 1/8 within 6 weeks after completing the ther-
apy. The patient was referred to the department of infec-
tious diseases for further tests and treatment of HIV infec-
tion. 
Discussion
Syphilis is a systemic illness, caused by the spirochete
Treponema pallidum. The World Health Organization
(WHO) estimates that there are 12 million new cases of
syphilis each year, with more than 90% occurring in devel-
oping countries [2]. Based on data from 2003-2004, it is
estimated that more than 60% of syphilis cases occur in
men who have sex with men (MSM). A large proportion
of these persons are also infected with HIV [1]. 
The disease has been arbitrarily divided into three
stages (primary, secondary and tertiary). Signs and
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symptoms of secondary syphilis typically begin 4-10
weeks after the appearance of a chancre (primary
syphilis lesion). Lesions of secondary syphilis result from
the hematogenous dissemination of treponemes from
syphilitic chancres. A frequent first manifestation of this
stage of the disease is an asymptomatic, delicate, light
red macular eruption found on the flanks. Untreated,
the macules disappear within 2 weeks. Subsequently,
the maculopapular or papulosquamous exanthema
appears affecting the hands and soles [3]. However, pus-
tular, papular, lichenoid, nodular, ulcerative, plaque-like,
annular and even urticarial and granulomatous forms
can occur [4-7]. Due to a large variety of skin manifes-
tations of secondary syphilis, the disease has to be dif-
ferentiated from a number of dermatological disorders.
Most common are: primary HIV, HIV immune reconsti-
tution syndrome, pityriasis rosea, psoriasis, erythema
multiforme, tinea versicolor, lichen planus, drug erup-
tions, viral exanthema, seborrheic dermatitis and sca-
bies. Secondary syphilis is a systemic process so gener-
al symptoms such as fatigue, malaise, sore throat, fever,
lymphadenopathy, muscular and joint pain may occur.
Renal, gastrointestinal and hepatic disease is also pos-
sible [8]. 
Some recent studies have suggested that syphilis in
HIV co-infected patients causes transient increases in the
viral load and decreases in the CD4 cell count increasing
the degree of immunosuppression [9]. Thus, the natural
course of syphilis may be altered in HIV positive patients.
HIV co-infection may be associated with multiple chan-
cres (up to 70% of patients) which are larger and deeper
than in HIV-uninfected persons. Approximately one fourth
of HIV-infected patients present with concomitant lesions
of both primary and secondary stages of syphilis at the
time of diagnosis. Additionally, significantly more HIV-pos-
itive patients present with more aggressive secondary dis-
ease, which is accompanied by greater constitutional
symptoms, greater organ involvement, atypical rashes,
and when treated with penicillin – a predilection for devel-
oping Jarish-Herxheimer-Lukasiewicz reaction [1]. More-
over, unusual and long-lasting syphilitic lesions in HIV 
coinfected patients may cause a significant delay in diag-
 nosis [10, 11]. 
In our patient we did not find the coexistence of chan-
cre and secondary syphilis lesions. The patient was with-
out general symptoms and Jarish-Herxheimer-Lukasiewicz
reaction did not occur.
Neurosyphilis can be divided into early and late forms.
Early neurosyphilis affects the CSF, cerebral blood vessels,
and meninges. It occurs within weeks to a few years after
primary infection, and may be asymptomatic. Sympto-
matic forms of early neurosyphilis include meningitis, with
or without cranial nerve or eye involvement, and meningo-
vascular disease or stroke. Late neurosyphilis affects brain
or spinal cord parenchyma, and usually occurs years to
decades after primary infection. Manifestations of late
neurosyphilis include general paresis, a rapidly progres-
sive dementia with psychotic features, and tabes dorsalis,
a spinal cord disorder with sensory ataxia and bowel and
bladder dysfunction [12]. 
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Figure 1. PLEVA-like syphilis. Papules and plaques on the
forehead
Figure 2. PLEVA-like syphilis. Scattered papules on the trunk.
Some lesions with central necrosis
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There is no criterion standard for the diagnosis of neu-
rosyphilis. In the appropriate clinical settings, CSF pleo-
cytosis of > 5 cells/mm3 and elevated CSF protein con-
centration are suggestive of neurosyphilis. The diagnosis
of neurosyphilis is more difficult in HIV-infected individ-
uals since up to 60% of them may demonstrate CSF
abnormalities including pleocytosis even without coex-
isting syphilis. In such cases, cutoff equal and greater than
20 cells/mm3 may be more specific for neurosyphilis diag-
nosis. In the absence of visible blood contamination,
a positive CSF-VDRL result is specific and establishes the
diagnosis of neurosyphilis; however, the sensitivity of CSF-
VDRL against clinical diagnosis is only 30% to 70%. In con-
trast, treponemal tests are sensitive, but nonspecific.
A negative CSF-FTA-abs and/or CSF-TPHA test result vir-
tually excludes the diagnosis of neurosyphilis [12]. 
In the presented case there was no doubt about the
diagnosis of neurosyphilis. The patient had both neuro-
logical symptoms (i.e. headache and photophobia) and
CSF abnormalities including positive CSF-VDRL result. 
Approximately one third of patients with early syphilis
have invasion of treponemes in the CSF, regardless of their
HIV status. If untreated, treponemes may either sponta-
neously clear from CNS, persist or progress clinically (i.e.
meningovascular syphilis or later form such as tabes dor-
salis) [12]. Its mechanism is unclear. However, it is believed
that HIV-infected individuals are less susceptible to clear
treponemes from CNS. Some case reports and retrospec-
tive studies found that neurosyphilis in HIV-infected indi-
viduals may occur more frequently and progress more
rapidly [13]. However, until now it has not been confirmed
in prospective trials. 
A recent study of Marra et al. found that persons with
serum RPR (Rapid Plasma Reagin) test titers of 1 : 32 or
higher and HIV-infected persons with CD4 cell counts of
350/µl or lower were at higher risk of CNS syphilis. Thus,
it has been suggested, as previously discussed, that HIV
associated immunodysregulation may account for the
impaired clearance of treponemes from CNS [14]. In our
patient the CD4 cells count was 430/µl. It suggested that
the host defense was not significantly impaired. Despite
that neurosyphilis has occurred. Thus, other than immuno-
logic factors of treponemes CNS spontaneous clearance
must be considered. 
According to the International Union Against Sexual-
ly Transmitted Infection (IUSTI), duration of the tre-
ponemocidal level of antimicrobial should be at least 
7-10 days to cover a number of division times (approxi-
mately 30 h). Thus, the first line therapy options in early
syphilis (i.e. primary, secondary and early latent) are: 
1) single dose of benzathine penicillin at a dose of 2.4 mil-
lion units intramuscularly (level of evidence Ib – obtained
from at least one randomized control trial) which provides
a treponemocidal penicillinaemia for up to 4 weeks or 
2) procaine penicillin of 600 000 units intramuscularly
daily for 10-14 days (level of evidence IIb – obtained from
at least other type of well-designed quasi-experimental
study). In cases of penicillin allergy, alternatives are: 
1) doxycycline of 200 mg daily for 14 days, 2) tetracycline
of 500 mg four times orally daily for 14 days (both have
the level of evidence III – obtained from well-designed
non-experimental descriptive studies), 3) erythromycin of
500 mg four times orally daily for 14 days (level of evi-
dence IV – obtained from expert committee reports or
opinions). Azithromycin shows good anti-treponemocidal
activity in animal studies and early open studies showed
that it appear effective in early syphilis [15]. However,
intrinsic resistance to azithromycin has been described
in some T. pallidum strains [16]. 
Despite controversies, current guidelines recommend
that treatment of early syphilis in patients with con-
comitant HIV infection should be given as for non-HIV-
infected patients. Some specialists recommend routine
CSF-examination in HIV-positive patients [15]. 
In our Department, because of the increased risk of
neurosyphilis, we perform lumbar puncture in all HIV-in -
fected patients. Additionally we define the degree of
immunosuppression by determining the CD4+ count and
HIV viral load. All patients with clinical and/or laboratory
findings consistent with neurosyphilis diagnosis are treat-
ed with neurosyphilis protocols (i.e. benzyl penicillin of
12-24 million units intravenously daily, as 3-4 million units
every 4 h during 18-21 days) [15]. 
In conclusion, after the advent of HIV infection epi-
demic, it may be more common to see cases of syphilis
with unusual presentation. Our case highlights the impor-
tance of syphilis testing in every case with atypical rash-
es. All patients who have syphilis should be also tested
for HIV infection. We would like to emphasize that even
mild and non-specific neurological symptoms such as
headache and/or photophobia in a patient with syphilis
may suggest neurosyphilis. 
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